Skip to main content
. 2019 Feb 26;8(1):CNS28. doi: 10.2217/cns-2018-0007

Figure 2. . Pseudoresponse.

Figure 2. 

(A) Axial T1-weighted contrast enhanced MRI of left frontal recurrent glioblastoma (a) before and (b) 1 day after therapy with cediranib (pan-VEGFR inhibitor) showing significant reduction in contrast enhancement. The reduction in contrast enhancement within 1 day of therapy is more likely to be caused by reduced vascular permeability to contrast than to a true antitumor effect. (Slide courtesy of A. Gregory Sorensen, Massachusetts General Hospital). (B) Pseudoresponse. Axial T1-weighted contrast enhanced MRI of right parietal glioblastoma (a) before and (b) 1 day after therapy with XL184 (VEGFR and MET inhibitor) showing significant reduction in contrast enhancement. (Slide courtesy of A. Gregory Sorensen, Massachusetts General Hospital).

(A) Adapted with permission from [20].